
NYSE:STZ
This summary was created by AI, based on 6 opinions in the last 12 months.
Constellation Brands Inc (STZ-N) is facing significant challenges in the current market, as indicated by multiple reviews from experts. The shift in consumer behavior, particularly among younger demographics opting for health-conscious choices and alternative substances like weed, poses a serious threat to traditional alcohol sales. Additionally, the impact of GLP-1 weight-loss drugs is contributing to decreased demand for alcoholic beverages, further exacerbating weak sales figures. The company has yet to demonstrate a substantial turnaround under its new CEO, despite some expert belief in potential future improvements. There is also concern regarding the social and political implications of the ongoing immigration discourse, which is reportedly affecting sales of their Mexican beer brands. Analysts remain skeptical, with many downgrading the stock and predicting a lackluster performance in upcoming earnings reports.
Last week, it reported stellar numbers but shares still fell, a victim to persistent misconceptions. Their Modelo is the #1 beer in the US and is gaining market share. Pacifico sales are up 21%. STZ operating margins were up 260 basis points. They beat Q1 EPS. Shares should be selling at $300. The problem is STZ also sells hard liquor, which Wall Street has given up on as well as doubts that beer's popularity is waning. Has huge free cash flow, are buying back shares, and is expanding facilities. Other threats are the weight-loss drugs and the popularity of cannabis. He won't abandon this stock though.
He's long owned this, but the stock has hit several road blocks including a bad investment in cannabis-maker Canopy Growth and the company founders selling huge amounts of shares. he's stuck with it, because he believes in their Mexican beers like Modelo. They just reported solid numbers, like an earnings beat, and a sunny forecast about beer sales even wine/spirits isn't doing as well. Is a long way from last year's highs, but is undervalued.
Stock has been sinking for months and faces concerns of the eight-loss drugs impacted their beer sales.